Getting semaglutide on the NHS: the real picture in 2025–26

What the NHS actually offers — and the conditions attached

Wegovy (semaglutide) was recommended by NICE in March 2023 under technology appraisal TA875, but the recommendation comes with firm boundaries. To receive it on the NHS, an adult generally needs a BMI of 35 or above and at least one weight-related comorbidity, conditions such as high blood pressure, type 2 diabetes, dyslipidaemia or obstructive sleep apnoea. For people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, the threshold is typically 2.5 kg/m² lower. Crucially, TA875 specifies that treatment must be delivered within a specialist weight management service, with multidisciplinary support including dietary, behavioural and activity components. It is not available through an ordinary GP appointment under this guidance. There is also a two-year maximum duration built into the recommendation, after which continuing treatment would need to be reviewed. If fewer than five percent of body weight has been lost after six months at the maintenance dose, NICE advises that continuing is unlikely to be worthwhile.

In practice, this means NHS England's waiting lists for tier 3 and tier 4 specialist services are long, referral criteria vary between integrated care boards, and not every part of the country has equivalent provision. NHS England's guidance on weight-management medicines sets out what services are expected to provide alongside the prescription, but that wraparound support is itself a resource that many areas are still building capacity for.

Ozempic, Wegovy and Rybelsus, why the semaglutide labelling matters on the NHS

Semaglutide is sold under more than one brand name in the UK, and that distinction matters enormously for NHS access. Ozempic is semaglutide at doses up to 1 mg, licensed for type 2 diabetes, not weight management. It is sometimes prescribed off-label, but the MHRA is clear that GLP-1 medicines are not assessed or licensed for quick or cosmetic weight loss, and NHS prescribing follows the licensed indication. Seeking Ozempic through a GP as a weight-loss medicine is not an NHS-supported route. Rybelsus is oral semaglutide, also for type 2 diabetes. Wegovy (the 2.4 mg weekly injection) is the only semaglutide product licensed in the UK specifically for weight management, and it is only available on the NHS through the specialist pathway described in TA875. The newer oral Wegovy tablet (approved by the MHRA on 11 June 2026) is not yet available on the NHS and would require a separate NICE appraisal first. If you are considering private treatment and want to buy a semaglutide pen through a regulated pharmacy, understanding which licensed product is appropriate for your situation is the right place to start. If you want to explore how semaglutide fits into the UK's weight-loss landscape more broadly, that page pulls together the full picture.

What to weigh up if NHS access isn't on the table for you

If your BMI sits below 35, if you don't have a qualifying comorbidity, or if your local waiting list makes NHS access practically unavailable in any reasonable timeframe, a private prescription is the legal route many people take. A private prescription for Wegovy requires a clinical assessment by a qualified prescriber, exactly as an NHS one does. The prescriber decides whether treatment is appropriate given your health history, current medicines and circumstances. What changes privately is that you do not need a specialist referral, and the assessment can happen quickly, at a GPhC-registered online pharmacy like nume, a named prescriber reviews your consultation the same day. The cost of private treatment is real, and worth thinking about honestly. Our Wegovy price context page lays out what private market pricing typically looks like and what a legitimate price should include, clinical review, prescription, supply and aftercare, not just the pen. People who have already reviewed their dose options and are ready to buy semaglutide 10mg will find that doing so through a verified, GPhC-registered pharmacy is the safest and most straightforward route. The safety infrastructure around semaglutide safety is the same whether the prescription comes from the NHS or a regulated private pharmacy; the medicine is identical. What matters is that it comes through a legitimate supply chain, from a pharmacy you can verify on the GPhC register.

The decision isn't simply NHS vs. private. It's a question of timeline, eligibility, personal circumstances and whether the clinical oversight at each route meets the standard you'd expect. If you want to understand the full process for obtaining semaglutide under either route, that page walks through every step. When you're ready to find out whether a private consultation is appropriate for you, speaking to our prescribers is a good starting point.